What Happened to Nuvation Bio?
Ticker: NUVBSPAC Year: 2020
Return
-56.5%
Current Price
$4.35
Peak Price
$15.23
Trust Size
$595M
Summary
Nuvation Bio is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer, with a pipeline targeting drug resistance and limited efficacy in current oncology treatments.
What Happened
Nuvation Bio went public in February 2021 through a merger with Panacea Acquisition Corp, a SPAC sponsored by EcoR1 Capital. Founded by veteran biotech executive David Hung (founder of Medivation, which was acquired by Pfizer for $14 billion), Nuvation Bio is advancing multiple oncology drug candidates including treatments for solid tumors and hematologic malignancies. The stock has traded below its SPAC price but has shown promise with clinical data readouts.
Timeline
2020-06-23
S-1 Registration Filed